CEFPROZIL TABLETS

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

CEFPROZIL (CEFPROZIL MONOHYDRATE)

Διαθέσιμο από:

RANBAXY PHARMACEUTICALS CANADA INC.

Φαρμακολογική κατηγορία (ATC):

J01DC10

INN (Διεθνής Όνομα):

CEFPROZIL

Δοσολογία:

500MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

CEFPROZIL (CEFPROZIL MONOHYDRATE) 500MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

SECOND GENERATION CEPHALOSPORINS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0127613002; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2009-08-20

Αρχείο Π.Χ.Π.

_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
CEFPROZIL TABLETS
CEFPROZIL TABLETS
(250 MG AND 500 MG OF CEFPROZIL AS CEFPROZIL MONOHYDRATE)
USP
ANTIBIOTIC
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
DATE OF REVISION:
October 9, 2019
CONTROL NO: 231653
_ _
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
OVERDOSAGE
...............................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 12
PART II: SCIENTIFIC INFORMATION
..............................................................................
13
PHARMACEUTICAL INFORMATION
.........................................................................
13
TOXICOLOGY
................................................................................................................
18
REFERENCES
.................................................................................................................
25
PART III: CONSUMER INFORMATION
.............................